Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of amlitelimab in moderate to severe atopic dermatitis
2021-000725-28Phase 2Active
- Sponsor
- Kymab
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (5 arms), sponsored by Kymab. Primary endpoint: Percentage change in Eczema Area and Severity Index from baseline to Day 113. Started Nov 2021; status: active.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-000725-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000725-28.